This content is for information only and does not replace medical advice
These stakeholders should assess their current practices and effectively transition during the brief window in which the FDA will employ enforcement discretion, or until April 22, 2025 for 503A pharmacies and until May 22, 2025 for 503B facilities
Monitoring appetite, energy levels, digestion, and blood sugar changes carefully may help patients recognise whether adjustments are needed early
Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose